Invivyd Inc (IVVD)
1.685
0.00 (0.00%)
USD |
NASDAQ |
Jun 10, 16:00
1.685
0.00 (0.00%)
After-Hours: 20:00
Invivyd Cash from Financing (Quarterly): 39.10M for March 31, 2024
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 39.10M |
| December 31, 2023 | 0.141M |
| September 30, 2023 | 0.092M |
| June 30, 2023 | 0.27M |
| March 31, 2023 | 0.542M |
| December 31, 2022 | 0.141M |
| September 30, 2022 | 0.246M |
| Date | Value |
|---|---|
| June 30, 2022 | 0.074M |
| March 31, 2022 | 0.045M |
| December 31, 2021 | -0.749M |
| September 30, 2021 | 328.60M |
| June 30, 2021 | 334.83M |
| March 31, 2021 | 0.00 |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-0.749M
Minimum
Dec 2021
334.83M
Maximum
Jun 2021
54.10M
Average
0.141M
Median
Dec 2022
Cash from Financing (Quarterly) Benchmarks
| Vanda Pharmaceuticals Inc | -- |
| Viking Therapeutics Inc | 606.04M |
| Stoke Therapeutics Inc | 1.717M |
| 180 Life Sciences Corp | -0.2644M |
| MAIA Biotechnology Inc | 4.717M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -50.21M |
| Cash from Investing (Quarterly) | -0.14M |
| Free Cash Flow | -182.33M |
| Free Cash Flow Per Share (Quarterly) | -0.4355 |
| Free Cash Flow Yield | -97.28% |